CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical …
initiation
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally …
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase …
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 …
Read more here:
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome
CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase II clinical …
View original post here:
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome